Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV-CNGA3 Gene Therapy for Achromatopsia
NCT03758404Phase 2Completed
- Sponsor
- MeiraGTx
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of aguracingene cadoparvovec in achromatopsia (ACHM), sponsored by MeiraGTx. Started Aug 2019; status: completed.
02
Drugs
aguracingene cadoparvovec
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on NCT03758404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758404.